Regeneron
Regeneron Pharmaceuticals, Inc., commonly referred to as Regeneron, is a leading biotechnology company headquartered in the United States. Founded in 1988, Regeneron has established itself as a pioneer in the development of innovative medicines, particularly in the fields of ophthalmology, oncology, and immunology.
With a strong focus on research and development, Regeneron is renowned for its unique products, including EYLEA® for eye diseases and Dupixent® for various allergic conditions. The company’s commitment to scientific excellence has positioned it as a key player in the biopharmaceutical industry, achieving significant milestones such as the rapid development of treatments during public health emergencies.
Regeneron continues to expand its global footprint, with major operations across North America and Europe, solidifying its reputation as a leader in advancing healthcare solutions.
+11 vs industry average
Regeneron’s score of 49 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Regeneron?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Regeneron's reported carbon emissions
In 2024, Regeneron Pharmaceuticals, Inc. reported total greenhouse gas emissions of approximately 1,465,520,000 kg CO2e. This figure includes Scope 1 emissions of about 80,300,000 kg CO2e, Scope 2 emissions of approximately 40,400,000 kg CO2e (market-based), and significant Scope 3 emissions totalling around 1,344,820,000 kg CO2e. Regeneron has set ambitious climate commitments, aiming to reduce its combined Scope 1 and 2 greenhouse gas emissions per square metre by 30% by 2025, using a 2016 peak baseline. This target reflects the company's focus on improving operational efficiency and reducing its carbon footprint. Additionally, by 2035, Regeneron plans to match 100% of its electricity consumption with certified renewable energy sources, further enhancing its sustainability efforts. The emissions data is sourced directly from Regeneron Pharmaceuticals, Inc. and is not cascaded from any parent or related organisation. The company is actively working towards its climate goals, demonstrating a commitment to environmental responsibility in the pharmaceutical industry.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Regeneron’s Climate Goals (2030 & 2050)
4 goals2035
By 2035, match 100% of our electricity consumption with elec…
By 2035, match 100% of our electricity consumption with electricity from certified renewable energy sources.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 4 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
7 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project